- Featured Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions 7 February 2025. Related: Special reports, Treatment access, Treatment advocacy.
- Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study 12 February 2025. Related: Weight, diabetes, metabolic complications, Coinfections and complications.
- News and resources linked to changes in US policy on international aid 7 February 2025. Related: Special reports.
- IAS public letter: Why HIV could be poised for a monumental comeback 6 February 2025. Related: Special reports, On the web.
- Lenacapavir for PrEP submitted to EMA for EU and global use 4 February 2025. Related: Antiretrovirals, HIV prevention and transmission.
- New mpox vaccination sites open in the UK 3 February 2025. Related: mpox.
- Future meetings and webinars 2025 1 February 2025. Related: Future meetings.
- Africa CDC special briefing on mpox and the impact of conflict 1 February 2025. Related: mpox.
- EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old 31 January 2025. Related: Antiretrovirals.
- US issues temporary waiver to re-enable PEPFAR 29 January 2025. Related: Treatment access.
- IAS statement: PEPFAR freeze threatens millions of lives 25 January 2025. Related: Treatment access.
- Trump bans travel for US government scientists, presentations restricted, documents disappearing 23 January 2025. Related: Treatment access, Treatment advocacy, Research studies.
- Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection 22 January 2025. Related: Special reports, Treatment strategies.
- BHIVA pregnancy guidelines online for comment: deadline 25 January 20 January 2025. Related: Pregnancy, Guidelines.
- Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1 6 January 2025. Related: mpox, IDWeek 2024.
- Tecovirimat news continues: Japan approval includes mpox indication 2 January 2025. Related: mpox.
- Looking back through 2024 and forward to 2025… 1 January 2025. Related: Editorial, Special reports.
- i-Base appeal: Q&A services and the website in 2025 1 January 2025. Related: Editorial, Special reports.
- ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir 1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals, HIV 17 Glasgow 2024.
- Transient impact of lenacapavir against MDR HIV-2 without other active ART 1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.
- Lenacapavir submitted to the US FDA with an indication for HIV PrEP 1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
- Chiva short films on children and HIV shortlisted for charity award 12 December 2024. Related: Paediatric care, Treatment advocacy, On the web.
- HIVR4P 2024 conference resources now open access 12 December 2024. Related: Conference reports, On the web, R4P 2024 Lima.
- Tecovirimat fails to show benefit in randomised STOMP study in mpox clade 2 10 December 2024. Related: mpox, Other news.
- IAS-USA 2024 guidelines for HIV treatment and prevention: some differences to EACS and UK 5 December 2024. Related: Guidelines.
- HTB news: i-Base changes during 2024 1 December 2024. Related: Editorial, Special reports.
- Glasgow HIV Congress 2024: Introduction and links 26 November 2024. Related: Conference reports, HIV 17 Glasgow 2024, Conference index.
- Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48 26 November 2024. Related: Conference reports, Antiretrovirals, HIV 17 Glasgow 2024.
- EACS guidelines: New format and contents includes chemsex 26 November 2024. Related: Conference reports, Guidelines, HIV 17 Glasgow 2024.
- Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours 26 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission, HIV 17 Glasgow 2024.
- Future PrEP and new results on lenacapavir from PURPOSE 1 and 2 – does HIV exposure explain incident cases? 26 November 2024. Related: Conference reports, HIV prevention and transmission, HIV 17 Glasgow 2024.
- Liverpool University Drug Interaction website recognised for global impact on research and care 26 November 2024. Related: Conference reports, PK and drug interactions, Treatment advocacy, HIV 17 Glasgow 2024.
- HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure 26 November 2024. Related: Conference reports, Hepatitis coinfection, HIV 17 Glasgow 2024.
- Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000 21 November 2024. Related: Conference reports, Antiretrovirals, HIV 17 Glasgow 2024.
- Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan 9 November 2024. Related: Special reports, Book and film reviews.
- WHO toolkit to strengthen engagement of health workers in emergency responses 5 November 2024. Related: On the web.
- Bipolar disorder in people living with HIV 1 November 2024. Related: Coinfections and complications.
- Mpox breakthrough cases after two doses of the MVA-BN vaccine 1 November 2024. Related: mpox.
- Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic 1 November 2024. Related: Treatment access, Paediatric care, Drug resistance.
- Confirmed mpox clade 1b case in Germany: risk remains low for EU/EEA 23 October 2024. Related: mpox.
- Helsinki Declaration: 2024 edition upholds ethical access to treatment 23 October 2024. Related: Treatment access, HIV prevention and transmission.
- Lack of tecovirimat activity against mpox clade 1 21 October 2024. Related: mpox, Coinfections and complications.
- Efficacy of MVA-BN vaccine: systematic review 21 October 2024. Related: mpox.
- Kidney transplants from HIV positive donors to HIV recipients 17 October 2024. Related: Coinfections and complications, Cancer and HIV.
- US NIAID updates HIV guide to person-centred language 17 October 2024. Related: Treatment advocacy, Book and film reviews, On the web.
- Long COVID essentials: link to online resources 15 October 2024. Related: On the web, COVID-19.
- HIVR4P 2024: Introduction 14 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission, Conference index, R4P 2024 Lima.
- Urgency of planning broad vaccine-like access to lenacapavir PrEP globally 13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission, R4P 2024 Lima.
- Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound 9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, R4P 2024 Lima.
- Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study 9 October 2024. Related: Conference reports, HIV prevention and transmission, R4P 2024 Lima.
